Clinical Trials Resource Center


July 2, 2012

Aeterna Zentaris reported results from a phase I trial of perifosine for the treatment of chemo-resistant and radio-resistant neuroblastoma. The open-label, dose-escalating study enrolled 24 patients who had been afflicted by neuroblastoma for 2.5 to 8.0 years. Subjects received 100-200mg/m2 perifosine on day one, followed by daily maintenance doses of 50-75mg/m2 perifosine as monotherapy. Anti-neuroblastoma activity was evident by a 50% progression-free survival rate at 12 months (standard error ±11%) and included one complete remission based on a normalized MIBG scan and three patients with improved MIBG scan and normalized bone marrow histology over prolonged follow-up (up to 37 months). The drug was well tolerated and safe, with no significant toxicity seen. Based on these data, Aeterna Zentaris will be pursuing perifosine as combination therapy.

Related Medical Areas

This information does not represent a Lupus Research Institute endorsement of any listed study. It is merely a notice that the study is available. If you are presently under the care of a physician for lupus or other conditions, you should not disrupt your current program without discussing it with your doctor(s). Do not contact the Lupus Research Institute for information on these studies. Only contact the listed numbers. The Lupus Research Institute does not have any jurisdiction over or further involvement with these studies, other than to make people aware that they are being conducted.